| Literature DB >> 23639672 |
Judit Sánchez-Castro1, Víctor Marco-Betés, Xavier Gómez-Arbonés, Leonor Arenillas, David Valcarcel, Teresa Vallespí, Dolors Costa, Benet Nomdedeu, María José Jimenez, Isabel Granada, Javier Grau, María T Ardanaz, Javier de la Serna, Félix Carbonell, José Cervera, Adriana Sierra, Elisa Luño, Carlos J Cervero, José Falantes, María J Calasanz, José R González-Porrás, Alicia Bailén, M Luz Amigo, Guillermo Sanz, Francesc Solé.
Abstract
The prognosis of chromosome 17 (chr17) abnormalities in patients with primary myelodysplastic syndrome (MDS) remains unclear. The revised International Prognostic Scoring System (IPSS-R) includes these abnormalities within the intermediate cytogenetic risk group. This study assessed the impact on overall survival (OS) and risk of acute myeloid leukemia transformation (AMLt) of chr17 abnormalities in 88 patients with primary MDS. We have compared this group with 1346 patients with primary MDS and abnormal karyotype without chr17 involved. The alterations of chr17 should be considered within group of poor prognosis. The different types of alterations of chromosome 17 behave different prognosis. The study confirms the intermediate prognostic impact of the i(17q), as stated in IPSS-R. The results of the study, however, provide valuable new information on the prognostic impact of alterations of chromosome 17 in complex karyotypes.Entities:
Mesh：
Year: 2013 PMID： 23639672 DOI： 10.1016/j.leukres.2013.04.010
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156